Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2- neu -positive breast cancer? A current debate

Author： Petrelli Fausto

Publisher： Humana Press, Inc

ISSN： 1357-0560

Source： Medical Oncology, Vol.28, Iss.2, 2011-06, pp. : 401-408

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer

By Xia Qing

Tumor Biology, Vol. 33, Iss. 5, 2012-10 ,pp. : 1719-1725

Springer Publishing Company

Access to resources Recommend Favorite

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

By Yardley Denise Burris Howard Peacock Nancy Raefsky Eric Melnik Marianne Inhorn Roger Shipley Dianna Hainsworth John

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 471-475

Springer Publishing Company

Access to resources Recommend Favorite

Identification of candidates for postmastectomy radiotherapy in patients with pT3N0M0 breast cancer

By Hamamoto Yasushi

Breast Cancer, Vol. 20, Iss. 3, 2013-07 ,pp. : 218-222

Springer Publishing Company

Access to resources Recommend Favorite

Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2positive patients with earlystage breast cancer

Oncology Letters, Vol. 8, Iss. 6, 2014-01 ,pp. : 2757-2761

Spandidos Publications

Access to resources Recommend Favorite

Prognostic Value of Quantitative Cytometry in a Series of 415 T1T2/N0N1/M0 Breast Cancer Patients--Preliminary Results

By Bolla M. Seigneurin D. Winckel P. Marron-Charriere J. Panh M.H. Pasquier D. Chedin M. Payan R. Merlin F. Colonna M.

European Journal of Cancer, Vol. 32, Iss. 10, 1996-09 ,pp. : 1680-1685

Elsevier

Access to resources Recommend Favorite